Investor Presentation

Acutaas Chemicals Reports 59.1% YoY Revenue Growth in Q1 FY27; Maintains 25% FY27 Growth Guidance

NSE

acutaas

BSE

543349

Acutaas Chemicals Limited reported a strong start to FY27, posting 59.1% year-on-year growth in revenue from operations to ₹329.7 crore and a 70.4% increase in profit after tax (PAT) to ₹75 crore during the quarter ended June 30, 2026.
The company also delivered significant margin expansion, reflecting improved operating leverage and product mix.
Management reaffirmed its confidence in achieving 25% revenue growth for FY27 while maintaining stable margins.
During the quarter, the company also received Great Place to Work® certification and the Responsible Care certification from the Indian Chemical Council, reinforcing its focus on sustainable growth and operational excellence.

PRICE-SENSITIVE TRIGGER

Event: Acutaas Chemicals announced its consolidated financial results for Q1 FY27 and reaffirmed its full-year revenue growth guidance.

Type: Investor Presentation

Impact: Positive

Immediate Effect: Strong earnings growth, improved profitability, and management’s reaffirmation of FY27 guidance provide positive signals regarding business momentum and execution.

Metrics:

Financial Metrics:

Revenue from Operations: ₹329.7 crore (+59.1% YoY, -23.8% QoQ)
Gross Profit: ₹190.9 crore (+73.0% YoY)
Gross Margin: 57.9% (vs 53.2% in Q1 FY26)
EBITDA: ₹113.1 crore (+122.1% YoY, -38.4% QoQ)
EBITDA Margin: 34.3% (vs 24.6% in Q1 FY26)
PAT: ₹75.0 crore (+70.4% YoY, -44.2% QoQ)
PAT Margin: 22.7% (vs 21.2% in Q1 FY26)

Highlight:

Acutaas Chemicals more than doubled EBITDA growth to 122.1% YoY while expanding EBITDA margin by nearly 970 basis points, reflecting strong operational efficiency and improved profitability.

What Happened ?

Acutaas Chemicals reported robust Q1 FY27 performance, supported by strong demand across its pharmaceutical intermediates and specialty chemicals portfolio. Revenue and profitability improved substantially over the corresponding quarter last year, with gross margins, EBITDA margins, and PAT margins all expanding.

Beyond financial performance, the company achieved two important organizational milestones during the quarter. It received Great Place to Work® certification, recognizing its workplace culture, and earned the Responsible Care certification from the Indian Chemical Council, demonstrating adherence to globally recognized standards of safety, health, and environmental performance.

key details

Strong Operating Performance and Business Momentum:

Revenue from operations increased 59.1% YoY to ₹329.7 crore.
Gross margin improved to 57.9%, expanding by 466 basis points over the previous year.
EBITDA more than doubled, rising 122.1% YoY to ₹113.1 crore.
EBITDA margin expanded to 34.3%, compared with 24.6% in Q1 FY26.
PAT increased 70.4% YoY to ₹75 crore, while PAT margin improved to 22.7%.
The company reaffirmed its expectation of delivering 25% revenue growth for FY27 with stable margins.
Acutaas received Great Place to Work® certification during the quarter.
The company also secured the Responsible Care certification, recognizing its commitment to safety, sustainability, and environmental stewardship.

Note:

Management attributed the quarter’s performance to the company’s agile operating model and its ability to consistently deliver products to customers while maintaining operational discipline.
The reaffirmation of FY27 guidance indicates confidence in demand visibility and execution capabilities despite a high base in the preceding quarter.

Risk Analysis

Summary:

While Acutaas reported strong year-on-year growth, sustaining its full-year guidance will depend on continued demand across pharmaceutical and specialty chemical markets, execution efficiency, and maintaining profitability amid changing industry conditions.

Key Risks:

Quarterly revenue and profitability declined sequentially from the exceptionally strong Q4 FY26.
Future performance depends on sustained demand from pharmaceutical and specialty chemical customers.
Margin stability will require continued operational efficiency and disciplined cost management.
Specialty chemical businesses remain exposed to fluctuations in raw material costs and global demand cycles.

Worst Case:

A slowdown in customer demand, adverse raw material price movements, or weaker export markets could affect the company’s ability to achieve its targeted 25% annual revenue growth while maintaining stable margins.

Risk Level: Medium

Company Commentary

According to Mr. Naresh Patel, Executive Chairman & Managing Director:

The company has started FY27 on a strong note with 59.1% YoY revenue growth.
The performance reflects the agility of Acutaas’ business model and its ability to consistently deliver to customers.
Great Place to Work® certification recognizes the company’s culture of trust, collaboration, and employee engagement.
Responsible Care certification reaffirms Acutaas’ commitment to safety, health, environmental performance, and sustainable growth.
Management remains confident of delivering 25% revenue growth for FY27 with stable margins.

Official Exchange Filing: Acutaas Chemicals Limited

Support our work by sharing